Compare Stocks: ANIX, LXEO, XFOR, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.84 -2.1%	$3.36	$2.32 ▼ $5.46	$96.63M	0.51	192,356 shs	403,951 shs
LRMR Larimar Therapeutics	$3.86 -5.3%	$3.93	$2.71 ▼ $6.42	$400.47M	0.74	2.62 million shs	700,342 shs
LXEO Lexeo Therapeutics	$4.52 -5.1%	$4.74	$3.99 ▼ $10.99	$370.46M	1.5	921,826 shs	174,540 shs
XFOR X4 Pharmaceuticals	$3.57 +1.6%	$4.06	$2.80 ▼ $4.83	$353.47M	0.39	570,737 shs	938,960 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-5.54%	-11.59%	-15.20%	+23.40%	-2.68%
LRMR Larimar Therapeutics	+6.27%	+3.30%	-2.16%	+18.31%	+3.56%
LXEO Lexeo Therapeutics	-2.66%	+1.28%	-1.04%	+15.25%	-9.33%
XFOR X4 Pharmaceuticals	-13.12%	-13.76%	-24.35%	-5.90%	+3.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.84 -2.1%	$3.36	$2.32 ▼ $5.46	$96.63M	0.51	192,356 shs	403,951 shs
LRMR Larimar Therapeutics	$3.86 -5.3%	$3.93	$2.71 ▼ $6.42	$400.47M	0.74	2.62 million shs	700,342 shs
LXEO Lexeo Therapeutics	$4.52 -5.1%	$4.74	$3.99 ▼ $10.99	$370.46M	1.5	921,826 shs	174,540 shs
XFOR X4 Pharmaceuticals	$3.57 +1.6%	$4.06	$2.80 ▼ $4.83	$353.47M	0.39	570,737 shs	938,960 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	-5.54%	-11.59%	-15.20%	+23.40%	-2.68%
LRMR Larimar Therapeutics	+6.27%	+3.30%	-2.16%	+18.31%	+3.56%
LXEO Lexeo Therapeutics	-2.66%	+1.28%	-1.04%	+15.25%	-9.33%
XFOR X4 Pharmaceuticals	-13.12%	-13.76%	-24.35%	-5.90%	+3.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$8.50	199.30% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	201.08% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.75	309.84% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	211.12% Upside

Current Analyst Ratings Breakdown

Latest ANIX, LXEO, XFOR, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/25/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/30/2026	LXEO Lexeo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.42 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A
XFOR X4 Pharmaceuticals	$35.11M	10.21	N/A	N/A	$2.13 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.31	N/A	N/A	N/A	N/A	-71.12%	-62.88%	9/9/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest ANIX, LXEO, XFOR, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/6/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
6/10/2026	Q2 2026	ANIX Anixa Biosciences	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	9.79	9.79
LRMR Larimar Therapeutics	N/A	4.70	4.70
LXEO Lexeo Therapeutics	N/A	13.89	13.89
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
LRMR Larimar Therapeutics	91.92%
LXEO Lexeo Therapeutics	60.67%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
LRMR Larimar Therapeutics	4.00%
LXEO Lexeo Therapeutics	2.00%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
LXEO Lexeo Therapeutics	58	82.05 million	80.41 million	Not Optionable
XFOR X4 Pharmaceuticals	80	99.15 million	98.03 million	No Data

ANIX, LXEO, XFOR, and LRMR Headlines

Recent News About These Companies

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

September 9 at 7:00 AM | globenewswire.com

X4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia Trial

September 8 at 11:37 AM | marketscreener.comM

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

September 8 at 7:00 AM | globenewswire.com

Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

September 3, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

August 13, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

August 11, 2026 | marketbeat.com

Equities Analysts Issue Forecasts for XFOR FY2029 Earnings

August 10, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 7, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 8,543 Shares

July 2, 2026 | insidertrades.com

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, LXEO, XFOR, and LRMR Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.84 -0.06 (-2.07%)

As of 03:39 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Larimar Therapeutics NASDAQ:LRMR

$3.86 -0.22 (-5.28%)

As of 03:55 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$4.51 -0.25 (-5.15%)

As of 03:55 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

X4 Pharmaceuticals NASDAQ:XFOR

$3.56 +0.06 (+1.57%)

As of 03:55 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, LXEO, XFOR, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, LXEO, XFOR, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, LXEO, XFOR, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, LXEO, XFOR, and LRMR Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, LXEO, XFOR, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, LXEO, XFOR, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, LXEO, XFOR, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, LXEO, XFOR, and LRMR Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools